Immuneering (IMRX) Enterprise Value (2020 - 2026)

Immuneering's Enterprise Value history runs 7 years deep, the most recent figure standing at -$156.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 336.89% year-over-year to -$156.7 million; the TTM figure through Mar 2026 stood at -$156.7 million (down 336.89% YoY), while the FY2025 annual figure was -$172.8 million, down 378.16% from the prior year.
• Enterprise Value was -$156.7 million for Q1 2026 at Immuneering, up from -$172.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$26.4 million in Q2 2025 to a low of -$227.6 million in Q3 2025.
• Historically, Enterprise Value has averaged -$100.5 million across 5 years, with a median of -$97.2 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 57.81% in 2024, then tumbled 378.16% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$105.5 million in 2022, then gained by 18.82% to -$85.7 million in 2023, then jumped by 57.81% to -$36.1 million in 2024, then sank by 378.16% to -$172.8 million in 2025, then rose by 9.34% to -$156.7 million in 2026.
• The last three Enterprise Value figures came in at -$156.7 million (Q1 2026), -$172.8 million (Q4 2025), and -$227.6 million (Q3 2025), per Business Quant data.